Effect of antidiabetic agents on hepatic functions in diabetic animals

Kakadiya, JagdishDr Jagdish L Kakadiya an academician and researcher in domain of Pharmacology for more than 8 years. Completed his PhD degree from JNU, M.Pharm (The M. S. University, Baroda) and B.Pharm. (L. M. College of Pharmacy, Ahmedabad) degree in year 2009 and 2005. He has also qualified GATE in 2007 (All India 23th Rank).

Type 2 diabetes is a progressive disorder with a consistent and steady increase in HbA1c over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. Administration of Streptozotocin (65 mg/kg, i.p) and Nicotinamide (110 mg/kg, i.p) produced symptoms such as hyperglycemia, loss of body weight. Also impaired glucose metabolism and altered hepatic function. The treatment with Metformin (50 mg/kg, p.o) reduced elevated levels of serum AST, ALT, ALP, GammaGTP and CPK levels which show the protective effect of Metformin (50 mg/kg/day, p.o). This study concluded that Glimepiride (0.5 mg/kg, p.o) alone and combination with Pioglitazone (10 mg/kg, p.o) and Metformin (50 mg/kg, p.o) may show some toxicity in STZ-NIC induced diabetic rats whereas with doses. Treatment with Pioglitazone (10 mg/kg, p.o), or combination thereof Metformin (50 mg/kg, p.o) and Glimepiride (0.5 mg/kg, p.o) showed a significant decrease in diabetic as compared to control nondiabetic rats and diabetic control rats indicate the toxicity in diabetic animal.